Business
After advancing in lockstep through the pandemic, the fortunes of the biotechs have diverged as their use of COVID-19 windfalls has taken shape.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 7, 2020.
San Francisco-based life sciences real estate development firm IQHQ completed the acquisition of a South San Francisco site known as South City Station.
Ventus Therapeutics, with offices in Waltham, Massachusetts and Montreal, closed on a $60 million Series A rounding led by founding investors Versant Ventures. GV, formerly Google Ventures, participated.
It is important to remember that this is a new virus, so researchers are constantly learning more about it every day.
Vaccine expert Rick Bright, who was abruptly dismissed from his post as director of the Biomedical Advanced Research and Development Authority (BARDA) last month, filed a whistleblower complaint against the administration over its failures to heed warnings about the COVID-19 pandemic and accused the White House of cronyism in awarding contracts.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 6, 2020.
Praxis is currently focused on leveraging its research on the genetics of epilepsy. Using its insights, the company is currently working on a pipeline of treatments that address the genes that control the imbalance of excitation and inhibition of neuronal circuitry.
In 1996, Udit Batra received his Ph.D. in chemical engineering from Princeton University. 24 years later, he heads a MilliporeSigma, $7.5 billion global life sciences company with a catalog of some 300,000 items used by life sciences researchers and developers throughout the world.
In an interview with National Geographic, Fauci once again sided with the evidence that indicates the virus is a species jumper and originated in the animal kingdom.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.